Advertisement
BIO vs COO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a Hold and COO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 0 FA rating(s) are green whileCOO’s FA Score has 0 green FA rating(s).
- BIO’s FA Score: 0 green, 5 red.
- COO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 4 TA indicator(s) are bullish while COO’s TA Score has 3 bullish TA indicator(s).
- BIO’s TA Score: 4 bullish, 4 bearish.
- COO’s TA Score: 3 bullish, 7 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а -7.16% price change this week, while COO (@Pharmaceuticals: Other) price change was -0.82% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.03%. For the same industry, the average monthly price growth was +0.41%, and the average quarterly price growth was +3.73%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.86%. For the same industry, the average monthly price growth was -3.35%, and the average quarterly price growth was +2.88%.
Reported Earning Dates
BIO is expected to report earnings on Oct 23, 2025.
COO is expected to report earnings on Aug 27, 2025.
Industries' Descriptions
@Medical/Nursing Services (-2.03% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+1.86% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| BIO | COO | BIO / COO | |
| Capitalization | 7.12B | 14B | 51% |
| EBITDA | 656M | 1.1B | 60% |
| Gain YTD | -19.573 | -23.540 | 83% |
| P/E Ratio | 23.82 | 33.96 | 70% |
| Revenue | 2.55B | 3.99B | 64% |
| Total Cash | 1.37B | 116M | 1,184% |
| Total Debt | 1.41B | 2.59B | 54% |
BIO | COO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 82 Overvalued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 85 | 84 | |
PRICE GROWTH RATING 1..100 | 58 | 64 | |
P/E GROWTH RATING 1..100 | 61 | 90 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
COO's Valuation (79) in the Medical Specialties industry is in the same range as BIO (82). This means that COO’s stock grew similarly to BIO’s over the last 12 months.
COO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BIO (100). This means that COO’s stock grew similarly to BIO’s over the last 12 months.
COO's SMR Rating (84) in the Medical Specialties industry is in the same range as BIO (85). This means that COO’s stock grew similarly to BIO’s over the last 12 months.
BIO's Price Growth Rating (58) in the Medical Specialties industry is in the same range as COO (64). This means that BIO’s stock grew similarly to COO’s over the last 12 months.
BIO's P/E Growth Rating (61) in the Medical Specialties industry is in the same range as COO (90). This means that BIO’s stock grew similarly to COO’s over the last 12 months.
| BIO | COO | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 54% | 4 days ago 74% |
| Stochastic ODDS (%) | 4 days ago 72% | 4 days ago 62% |
| Momentum ODDS (%) | 4 days ago 73% | 4 days ago 57% |
| MACD ODDS (%) | 4 days ago 65% | 4 days ago 60% |
| TrendWeek ODDS (%) | 4 days ago 64% | 4 days ago 58% |
| TrendMonth ODDS (%) | 4 days ago 69% | 4 days ago 59% |
| Advances ODDS (%) | 18 days ago 68% | 4 days ago 62% |
| Declines ODDS (%) | 4 days ago 67% | 6 days ago 58% |
| BollingerBands ODDS (%) | 4 days ago 69% | 4 days ago 63% |
| Aroon ODDS (%) | 4 days ago 58% | 4 days ago 54% |
Advertisement
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.
COO and
Correlation & Price change
A.I.dvisor indicates that over the last year, COO has been loosely correlated with ALC. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then ALC could also see price increases.